Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Why organized players like Titan Company could emerge bigger winners in India’s evolving gold market
India's gold market is rapidly formalizing despite high prices and tax hikes. Resilient consumer demand, especially for investment, favors organized players like Titan. Titan, leveraging Tanishq's brand strength, is projected for significant growth, modeling a sales/EBITDA/PAT CAGR of ~15%/20%/24% over FY26–28.
Aditya Birla Capital Plans To Use Rs 3,500 Crore To Drive Lending Business Growth
Earlier this week, the financial services arm of Aditya Birla Group announced a Rs 4,000 crore preferential issue of equity shares to the group companies and International Finance Corporation (IFC).
Retail health premium growth rises to 31% YoY in April 2026, anchoring non-life insurance sector: Kotak Institutional Securities
Indian non-life insurance saw robust growth in April 2026. Retail health premiums surged 31 percent year-on-year. Motor insurance also performed well. Private players and standalone health insurers are gaining market share from public sector companies. Commercial lines faced challenges, though marine and engineering segments showed resilience. This indicates a dynamic shift in the insurance landscape.
Sun Pharma Q4 Results: Drugmaker shares fall after earnings miss; US sales at $459 million
Sun Pharma's US formulations sales fell 1.1% from last year to $459 million during the March quarter. For the full year, the growth was a negative 0.9%.
Aditya Birla Group stocks: Grasim hits new peak; Voda Idea up 46% in 1-mth
Grasim is the flagship company of Aditya Birla Group, which is led by Kumar Mangalam Birla; while, the group holds substantial stake in Vodafone Idea.
Aditya Birla Capital plans to use Rs 3,500 crore to drive business growth
Aditya Birla Capital plans to invest Rs 3,500 crore from its recent fundraise into business expansion. Another Rs 500 crore will support general corporate needs and subsidiary investments. The company is raising Rs 4,000 crore through a preferential issue. Grasim Industries will contribute Rs 2,880 crore. IFC will invest Rs 920 crore.
High gold prices, import duty hike to drag jewellery demand: Crisil
Indian organized gold jewellery retailers anticipate a 13-15% sales volume decline this fiscal due to high gold prices and import curbs. Despite this, robust revenue growth of 20-25% is expected, driven by higher realisations, leading to stable credit profiles.
Aditya Birla Fashion among 5 stocks flashing bullish signals, hinting at a possible uptrend
Five Nifty500 stocks that gained over 5% appeared on the White Marubozu bullish scanner on May 21, signalling strong buying momentum. The candlestick pattern reflects sustained bullish pressure throughout the session, indicating buyers dominated price action and suggesting a potential continuation of the uptrend in the near term.
Aditya Birla Group bets big on IPL boom, says media rights frenzy is far from over
Aditya Birla Group sees strong future growth for Indian sports. The group believes IPL media rights will keep increasing in value. This is despite current worries about fewer bidders. India's economy and sports viewership are rising. Premium sports assets are also scarce. This supports future valuations. The group recently bought Royal Challengers Bengaluru. They are optimistic about the long-term trend.
LIC profit rises 23% in March quarter on all-round show
Life Insurance Corp announced a strong March quarter profit, up 23% to ₹23,467 crore. This growth was fueled by increased premiums and investment income. For the full year, profit after tax rose 19%. The company anticipates geopolitical tensions may affect savings flows. LIC is focusing on protection products and expects continued double-digit growth in new business premiums.
LIC Q4 Results: Profit rises 23% YoY to Rs 23,467 crore; co declares Rs 10 per share dividend
LIC Q4 Results: State-owned Life Insurance Corp (LIC) reported a 23% year-on-year (YoY) growth in its consolidated net profit at Rs 23,467 crore in the fourth quarter of FY26, compared with Rs 19,039 crore in the last-year period.
Sun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?
Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formulations, and emerging markets. Brokerages highlight US portfolio strength, new launches like Unloxcyt, and a steady margin outlook despite higher R&D spending, with EBITDA growth supported by diversified global business momentum outlook